Qilian International Holding Group Limited (BGM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Qilian International Holding Group Limited stock (BGM) is currently trading at $0.55. Qilian International Holding Group Limited PS ratio (Price-to-Sales) is 4.03. WallStSmart rates BGM as Sell.
- BGM PE ratio analysis and historical PE chart
- BGM PS ratio (Price-to-Sales) history and trend
- BGM intrinsic value — DCF, Graham Number, EPV models
- BGM stock price prediction 2025 2026 2027 2028 2029 2030
- BGM fair value vs current price
- BGM insider transactions and insider buying
- Is BGM undervalued or overvalued?
- Qilian International Holding Group Limited financial analysis — revenue, earnings, cash flow
- BGM Piotroski F-Score and Altman Z-Score
- BGM analyst price target and Smart Rating
Qilian International Holding Group
📊 No data available
Try selecting a different time range
Smart Analysis
Qilian International Holding Group Limited (BGM) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Qilian International Holding Group Limited (BGM) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Qilian International Holding Group Limited (BGM) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -56.90%, a shrinking business
Company is losing money with a negative profit margin
Very low institutional interest at 0.00%
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 4.0x annual revenue
Qilian International Holding Group Limited (BGM) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.66) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (4.03) suggest expensive pricing. Growth concerns include Revenue Growth at -56.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -16.50%, Operating Margin at -5.41%, Profit Margin at -26.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -16.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -56.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BGM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BGM's Price-to-Sales ratio of 4.03x trades 39% below its historical average of 6.56x (0th percentile). The current valuation is 50% below its historical high of 8.06x set in Mar 2026, and 0% above its historical low of 4.03x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~7.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Qilian International Holding Group Limited (BGM) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Qilian International Holding Group Limited is in a turnaround phase, with management focused on restoring profitability. Revenue reached 30M with 57% decline year-over-year. The company is currently unprofitable, posting a -26.3% profit margin.
Key Findings
Revenue contracted 57% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -26.3% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Qilian International Holding Group Limited.
Bottom Line
Qilian International Holding Group Limited is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Qilian International Holding Group Limited(BGM)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company is headquartered in Jiuquan, the People's Republic of China.